|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC85B |
Gene summary for CCDC85B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC85B | Gene ID | 11007 |
| Gene name | coiled-coil domain containing 85B | |
| Gene Alias | DIPA | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q15834 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11007 | CCDC85B | CA_HPV_1 | Human | Cervix | CC | 7.58e-12 | -1.75e-01 | 0.0264 |
| 11007 | CCDC85B | N_HPV_1 | Human | Cervix | N_HPV | 4.13e-02 | 5.67e-02 | 0.0079 |
| 11007 | CCDC85B | CCI_1 | Human | Cervix | CC | 4.39e-07 | -5.19e-01 | 0.528 |
| 11007 | CCDC85B | CCI_3 | Human | Cervix | CC | 7.49e-04 | -4.42e-01 | 0.516 |
| 11007 | CCDC85B | CCII_1 | Human | Cervix | CC | 3.54e-11 | -5.07e-01 | 0.3249 |
| 11007 | CCDC85B | H2 | Human | Cervix | HSIL_HPV | 6.52e-04 | -2.57e-01 | 0.0632 |
| 11007 | CCDC85B | L1 | Human | Cervix | CC | 1.67e-04 | -1.35e-01 | 0.0802 |
| 11007 | CCDC85B | HTA11_696_2000001011 | Human | Colorectum | AD | 2.26e-02 | 1.62e-01 | -0.1464 |
| 11007 | CCDC85B | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.97e-12 | 4.11e-01 | -0.059 |
| 11007 | CCDC85B | HTA11_866_3004761011 | Human | Colorectum | AD | 9.27e-09 | 2.78e-01 | 0.096 |
| 11007 | CCDC85B | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.47e-02 | 2.88e-01 | 0.0446 |
| 11007 | CCDC85B | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.03e-05 | 2.49e-01 | 0.0674 |
| 11007 | CCDC85B | HTA11_6818_2000001011 | Human | Colorectum | AD | 4.67e-04 | 2.18e-01 | 0.0112 |
| 11007 | CCDC85B | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.34e-11 | 4.89e-01 | 0.0588 |
| 11007 | CCDC85B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.81e-10 | 3.07e-01 | 0.294 |
| 11007 | CCDC85B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 9.62e-04 | 2.15e-01 | 0.281 |
| 11007 | CCDC85B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.22e-53 | 1.06e+00 | 0.3859 |
| 11007 | CCDC85B | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.44e-03 | 3.15e-01 | 0.2585 |
| 11007 | CCDC85B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.36e-22 | 5.56e-01 | 0.3005 |
| 11007 | CCDC85B | A002-C-116 | Human | Colorectum | FAP | 7.81e-03 | 3.17e-01 | -0.0452 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00015589 | Endometrium | AEH | regulation of cell growth | 75/2100 | 414/18723 | 1.79e-05 | 3.65e-04 | 75 |
| GO:00459264 | Endometrium | AEH | negative regulation of growth | 47/2100 | 249/18723 | 2.36e-04 | 2.84e-03 | 47 |
| GO:00303082 | Endometrium | AEH | negative regulation of cell growth | 36/2100 | 188/18723 | 9.15e-04 | 8.37e-03 | 36 |
| GO:00455981 | Endometrium | AEH | regulation of fat cell differentiation | 26/2100 | 139/18723 | 6.04e-03 | 3.64e-02 | 26 |
| GO:001604915 | Endometrium | EEC | cell growth | 95/2168 | 482/18723 | 1.16e-07 | 5.54e-06 | 95 |
| GO:000155814 | Endometrium | EEC | regulation of cell growth | 77/2168 | 414/18723 | 1.64e-05 | 3.16e-04 | 77 |
| GO:004592611 | Endometrium | EEC | negative regulation of growth | 48/2168 | 249/18723 | 2.58e-04 | 2.98e-03 | 48 |
| GO:00303081 | Endometrium | EEC | negative regulation of cell growth | 37/2168 | 188/18723 | 8.33e-04 | 7.67e-03 | 37 |
| GO:00454446 | Endometrium | EEC | fat cell differentiation | 39/2168 | 229/18723 | 8.69e-03 | 4.71e-02 | 39 |
| GO:001604919 | Esophagus | HGIN | cell growth | 93/2587 | 482/18723 | 4.49e-04 | 6.62e-03 | 93 |
| GO:000155818 | Esophagus | HGIN | regulation of cell growth | 76/2587 | 414/18723 | 5.40e-03 | 4.42e-02 | 76 |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:00454449 | Esophagus | ESCC | fat cell differentiation | 135/8552 | 229/18723 | 3.38e-05 | 2.78e-04 | 135 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:00455984 | Esophagus | ESCC | regulation of fat cell differentiation | 79/8552 | 139/18723 | 5.23e-03 | 1.97e-02 | 79 |
| GO:001604911 | Liver | Cirrhotic | cell growth | 160/4634 | 482/18723 | 1.50e-05 | 2.07e-04 | 160 |
| GO:000155811 | Liver | Cirrhotic | regulation of cell growth | 132/4634 | 414/18723 | 5.53e-04 | 4.36e-03 | 132 |
| GO:00454442 | Liver | Cirrhotic | fat cell differentiation | 73/4634 | 229/18723 | 8.57e-03 | 3.97e-02 | 73 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC85B | SNV | Missense_Mutation | novel | c.533N>C | p.Leu178Pro | p.L178P | Q15834 | protein_coding | tolerated(0.26) | possibly_damaging(0.539) | TCGA-43-8115-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |